



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Cwm Taf Morgannwg  
University Health Board



## Freedom of Information Request: Our Reference CTMUHB\_461\_25

**You asked:**

**I have a freedom of information request.**

### 1. How many patients have been treated with the following drugs in the past 4 months:

- **Atogepant (Aquipta) – any disease**
- **Erenumab (Aimovig) - any disease**
- **Eptinezumab (Vyepti) – any disease**
- **Fremanezumab (Ajovy) - any disease**
- **Galcanezumab (Emgality) - any disease**
- **Rimegepant (Vydura) – any disease**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**

Please find below, two tables populated with the data that Medicines Management are able to provide in relation to your enquiry.

The data provided for the latest 4 months available which is 1st June to 30<sup>th</sup> September 2025.

| Medicine                              | Number of Patients |
|---------------------------------------|--------------------|
| Atogepant (Aquipta) – any disease     | 24                 |
| Erenumab (Aimovig) - any disease      | 12                 |
| Eptinezumab (Vyepti) – any disease    | 0                  |
| Fremanezumab (Ajovy) - any disease    | 49                 |
| Galcanezumab (Emgality) - any disease | 27                 |
| Rimegepant (Vydura) – any disease     | 170                |

| Medicine                                                              | Number of Issues                                                                                                                                                                                                                                                                                     |
|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - <b>migraine ONLY</b> | Data on issue by indication (migraine) is not centrally recorded. The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the |

**2. How many patients have you treated in the last 4 months for acute migraine with:**

- **Rimegepant (Vydura)**

Data on issue by indication (acute migraine) is not centrally recorded. The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

**3. Are you required to complete Blueteq for the following product classes:**

- **Botulinum Toxin (Botox, Dysport, Xeomin)**
- **Monoclonal antibodies (e.g. fremanezumab, erenumab, galcanezumab, eptinezumab)**
- **Gepants (e.g. rimegepant, atogepant)**

At this current time BlueTeq forms are not required to be completed for the following:

- Botulinum Toxin (Botox, Dysport, Xeomin)
- Monoclonal antibodies (e.g. fremanezumab, erenumab, galcanezumab, eptinezumab)
- Gepants (e.g. rimegepant, atogepant)